Abstract: Peptides that generate an immune response to glioma-related H3.3 proteins and methods of their use are provided.

Abstract: This invention provides an isolated or purified T-cell receptor (TCR) having antigenic specificity for the mutated human p53R175H. The inventive TCR can recognize the HLA-A2 restricted mutant p53R175H peptide (HMTEVVRHC) but cannot recognize the wild-type p53R175 peptide (HMTEVVRRC). The inventive TCR can also be activated by tumor cells harboring a mutated human p53R175H in the context of HLA-A2. The invention further provides related polypeptides, proteins, nucleic acids, recombinant expression vectors, host cells, populations of cells and pharmaceutical compositions relating to the TCR of the invention. Methods of treating or preventing cancer in a mammal are further provided by the invention.

Abstract: This invention provides an isolated or purified T-cell receptor (TCR) having antigenic specificity for the mutated human CTNNB1S37F. The inventive TCR can recognize the HLA-A2 restricted mutant CTNNB1S37F peptide (YLDSGIHFGA) but cannot recognize the wild-type CTNNB1S37 peptide (YLDSGIHSGA). The inventive TCR can also be activated by tumor cells harboring a mutated human CTNNB1S37F in the context of HLA-A2. The invention further provides related polypeptides, proteins, nucleic acids, recombinant expression vectors, host cells, populations of cells and pharmaceutical compositions relating to the TCR of the invention. Methods of treating or preventing cancer in a mammal are further provided by the invention.

Abstract: Peptides that generate an immune response to glioma-related H3.3 proteins and methods of their use are provided.

Abstract: A therapeutic agent comprising a nucleic acid and a TCR modified immune cell and use thereof. The therapeutic agent comprises a first composition comprising a first active ingredient and a second composition comprising a second active ingredient. The first active ingredient includes or contains a nucleic acid having a labeling polypeptide coding sequence for being introduced into a tumor cell and/or a cancer cell. The labeling polypeptide has one or more epitope polypeptides which can be presented on a surface of the tumor cell and/or cancer cell by MHC class I molecules. The second composition comprises a second active ingredient in a second pharmaceutically acceptable carrier and the second active ingredient comprises a T cell receptor modified immune cell which can specifically recognize and bind to the epitope polypeptide presented by MHC class I molecules. The therapeutic agent achieves synergistic treatment effect and provides a new route for tumor treatment.

Abstract: A therapeutic agent and method of administering the therapeutic agent for the treatment of tumors and/or cancers of a subject, the therapeutic agent comprising a first pharmaceutical composition comprising a first active ingredient in a first druggable vehicle, wherein the first active ingredient comprises a nucleic acid encoding a labelling polypeptide comprising one or more antigenic epitope peptides and/or encoding a MHC protein; a second pharmaceutical composition comprising a second active ingredient in a second druggable vehicle, wherein the second active ingredient comprises immune cells purified from peripheral blood or from tumor tissue and are cultured in vitro; wherein the nucleic acid when administered to the subject as part of the pharmaceutical composition causes the tumor cells and/or cancer cells of the subject to express the one or more antigenic epitope peptides to elicit an immune response of the immune cells.

Abstract: Peptides that generate an immune response to glioma-related H3.3 proteins and methods of their use are provided.

Abstract: A therapeutic agent comprising a nucleic acid and a TCR modified immune cell and use thereof. The therapeutic agent comprises a first composition comprising a first active ingredient and a second composition comprising a second active ingredient. The first active ingredient includes or contains a nucleic acid having a labeling polypeptide coding sequence for being introduced into a tumor cell and/or a cancer cell. The labeling polypeptide has one or more epitope polypeptides which can be presented on a surface of the tumor cell and/or cancer cell by MHC class I molecules. The second composition comprises a second active ingredient in a second pharmaceutically acceptable carrier and the second active ingredient comprises a T cell receptor modified immune cell which can specifically recognize and bind to the epitope polypeptide presented by MHC class I molecules. The therapeutic agent achieves synergistic treatment effect and provides a new route for tumor treatment.

Abstract: Peptides that generate an immune response to glioma-related H3.3 proteins and methods of their use are provided.

Abstract: Peptides that generate an immune response to glioma-related H3.3 proteins and methods of their use are provided.

Abstract: Peptides that generate an immune response to glioma-related H3.3 proteins and methods of their use are provided.

Abstract: A therapeutic agent and method of administering the therapeutic agent for the treatment of tumors and/or cancers of a subject, the therapeutic agent comprising a first pharmaceutical composition comprising a first active ingredient in a first druggable vehicle, wherein the first active ingredient comprises a nucleic acid encoding a labelling polypeptide comprising one or more antigenic epitope peptides and/or encoding a MHC protein; a second pharmaceutical composition comprising a second active ingredient in a second druggable vehicle, wherein the second active ingredient comprises immune cells purified from peripheral blood or from tumor tissue and are cultured in vitro; wherein the nucleic acid when administered to the subject as part of the pharmaceutical composition causes the tumor cells and/or cancer cells of the subject to express the one or more antigenic epitope peptides to elicit an immune response of the immune cells.

Abstract: Peptides that generate an immune response to glioma-related H3.3 proteins and methods of their use are provided.

Abstract: Peptides that generate an immune response to glioma-related H3.3 proteins and methods of their use are provided.

Abstract: Peptides that generate an immune response to glioma-related H3.3 proteins and methods of their use are provided.

Abstract: Provided is an information management device including: a communication information obtaining unit configured to obtain communication information about a communication state in an internal network inside a building; and an update determination unit configured to determine a start of updating process by an information updating unit, based on the communication information obtained by the communication information obtaining unit, wherein the information updating unit obtains information from an external network outside the building and performs the updating process for storing the obtained information as local information into a storage device which is accessible, not via the external network, by a terminal device connected to the internal network.

Abstract: A composite cable (4) houses a plurality of leaky coaxial cables having mutually different radiation characteristics. The leaky coaxial cable (2a, 2b) includes therein an inner conductor and an outer conductor, and has a plurality of leakage slots. The plurality of leakage slots have different slot periods relative to the axial direction or arranged in different slot patterns. The digital wireless communication device feeds a high-frequency signal from an end of the composite cable (4) and performs MIMO (multiple-input multiple-output) communication.

Abstract: A composite cable (4) houses a plurality of leaky coaxial cables having mutually different radiation characteristics. The leaky coaxial cable (2a, 2b) includes therein an inner conductor and an outer conductor, and has a plurality of leakage slots. The plurality of leakage slots have different slot periods relative to the axial direction or arranged in different slot patterns. The digital wireless communication device feeds a high-frequency signal from an end of the composite cable (4) and performs MIMO (multiple-input multiple-output) communication.

Abstract: Peptides that generate an immune response to glioma-related H3.3 proteins and methods of their use are provided.

Abstract: Provided is an information management device including: a communication information obtaining unit configured to obtain communication information about a communication state in an internal network inside a building; and an update determination unit configured to determine a start of updating process by an information updating unit, based on the communication information obtained by the communication information obtaining unit, wherein the information updating unit obtains information from an external network outside the building and performs the updating process for storing the obtained information as local information into a storage device which is accessible, not via the external network, by a terminal device connected to the internal network.